Inactive Instrument

Celltrion Healthcare Co., Ltd.

Equities

A091990

KR7091990002

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Celltrion's Shares Climb After Merger With Affiliate DJ
Celltrion Concludes Merger with Celltrion Healthcare MT
Celltrion, Inc. completed the acquisition of a 64.46% stake in Celltrion Healthcare Co., Ltd. CI
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on November 9, 2023. CI
Celltrion Healthcare Co., Ltd.(KOSDAQ:A091990) dropped from FTSE All-World Index CI
Celltrion Healthcare Co., Ltd.(KOSDAQ:A091990) dropped from S&P Global BMI Index CI
Celltrion Healthcare Co., Ltd.'s Equity Buyback announced on November 9, 2023, has closed with 1,320,000 shares, representing 0.83% for KRW 96,505.56 million. CI
S.Korean shares end slightly higher as chipmakers advance; US CPI in focus RE
Celltrion Healthcare Co., Ltd. announces an Equity Buyback for 1,320,000 shares. CI
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on October 23, 2023. CI
Celltrion Healthcare Co., Ltd. authorizes a Buyback Plan. CI
Celltrion Healthcare Co., Ltd.'s Equity Buyback announced on October 23, 2023, has closed with 2,440,000 shares, representing 1.52% for KRW 164,432.92 million. CI
Celltrion Healthcare to Provide Turkmenistan with Two Anti-Cancer Medications MT
Celltrion Healthcare Co., Ltd. announces an Equity Buyback for 2,440,000 shares. CI
Celltrion Healthcare Co., Ltd. authorizes a Buyback Plan. CI
Celltrion Healthcare Presents Phase III Data from the LIBERTY-CD and LIBERTY-UC Clinical Trials CI
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on August 28, 2023. CI
Celltrion Healthcare Co., Ltd.'s Equity Buyback announced on August 28, 2023 has closed with 690,000 shares, representing 0.43% for KRW 45,263.26 million. CI
Celltrion Healthcare Co., Ltd. announces an Equity Buyback for 690,000 shares. CI
Celltrion Healthcare Co., Ltd. authorizes a Buyback Plan. CI
South Korean Shares Decline on Concerns over US Fed Rate Hike, China Economic Turmoil MT
South Korean shares post biggest weekly fall in 11 months RE
Celltrion Discloses Merger Plans with Celltrion HealthCare; Celltrion Shares Jump 5% MT
South Korean shares set for biggest weekly loss so far in 2023 RE
Tranche Update on Celltrion Healthcare Co., Ltd.'s Equity Buyback Plan announced on July 6, 2023. CI
Chart Celltrion Healthcare Co., Ltd.
More charts
Celltrion Healthcare Co Ltd is a Korea-based company principally engaged in the marketing and distribution of biopharmaceuticals. The Company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn's disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of non-Hodgkin lymphomas, chronic lymphocytic leukemia and rheumatoid arthritis. The Company distributes its products in domestic and overseas markets.
More about the company
  1. Stock
  2. Equities
  3. Stock Celltrion Healthcare Co., Ltd. - Korea S.E.
  4. News Celltrion Healthcare Co., Ltd.
  5. Celltrion Healthcare to Provide Turkmenistan with Two Anti-Cancer Medications
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW